Acyclic Nucleoside Phosphonates: A New Dimension To The Chemotherapy Of Dna Virus And Retrovirus Infections

References

1. De Clercq E. Trends in the development of new antiviral agents for the chemotherapy of infections caused by herpesviruses and retroviruses. Rev Med Virol 1995; 5:149–164
   [Google Scholar]
2. Field A. K., Biron K. K. “The end of innocence” revisited: resistance of herpesviruses to antiviral drugs. Clin Microbiol Rev 1994; 7:1–13
   [Google Scholar]
3. De Clercq E. Broad-spectrum anti-DNA virus and antiretrovirus activity of phosphonyl-methoxyalkylpurines and-pyrimidines. Biochem Pharmacol 1991; 42:963–972
   [Google Scholar]
4. Cihlar T., Chen M. S. Identification of enzymes catalyzing two-step phosphorylation of cidofovir and the effect of cytomegalovirus infection on their activities in host cells. Mol Pharmacol 1996; 50:1502–1510
   [Google Scholar]
5. Balzarini J., Nave J. F., Becker M. A., Tatibana M., De Clercq E. Kinetic properties of adenine nucleotide analogues against purified 5-phosphoribosyl-l-pyrophosphate synthetases from E. coli, rat liver and human erythrocytes. Nucleosides Nucleotides 1995; 14:1861–1871
   [Google Scholar]
6. Merta A., Votruba I., Jindrich J. Phosphorylation of 9-(2-phosphonomethoxyethyl)adenine by AMP (dAMP) kinase from L1210. Biochem Pharmacol 1992; 44:2067–2077
   [Google Scholar]
7. Naesens L., Snoeck R., Andrei G., Balzarini J., Neyts J., De Clercq E. HPMPC (cidofovir), PMEA (adefovir) and related acyclic nucleoside phosphonate analogues: a review of their pharmacology and clinical potential in the treatment of viral infections. Antiviral Chem Chemother 1997; 8:1–23
   [Google Scholar]
8. Kramata P., Votruba I., Otová B., Holý A. Different inhibitory potencies of acyclic phosphonomethoxyalkyl nucleotide analogs toward DNA polymerases α, and ε. Mol Pharmacol 1996; 49:1005–1011
   [Google Scholar]
9. Cihlar T., Chen M. S. Incorporation of selected nucleoside phosphonates and anti-human immunodeficiency virus nucleotide analogues into DNA by human DNA polymerases a, β and γ. Antiviral Chem Chemother 1997; 8:187–195
   [Google Scholar]
10. Xiong X., Smith J. L., Chen M. S. Effect of incorporation of cidofovir into DNA by human cytomegalovirus DNA polymerase on DNA elongation. Antimicrob Agents Chemother 1997; 41:594–599
    [Google Scholar]
11. De Clercq E. Therapeutic potential of HPMPC as an antiviral drug. Rev Med Virol 1993; 3:85–96
    [Google Scholar]
12. De Clercq E. Therapeutic potential of cidofovir (HPMPC, Vistide™) for the treatment of DNA virus (i.e. herpes-, papova-, pox-and adenovirus) infections. Verh K Acad Geneeskd Belg 1996; 58:19–49
    [Google Scholar]
13. Kedes D. H., Ganem D. Sensitivity of Kaposi’s sarcoma-associated herpesvirus replication to antiviral drugs. J Clin Invest 1997; 99:2082–2086
    [Google Scholar]
14. Reymen D., Naesens L., Balzarini J., Holy A., Dvoráková H., De Clercq E. Antiviral activity of selected acyclic nucleoside analogues against human herpesvirus 6. Antiviral Res 1995; 28:343–357
    [Google Scholar]
15. Takahashi K., Suzuki M., Iwata Y., Shigeta S., Yamanishi K., De Clercq E. Selective activity of various nucleoside and nucleotide analogues against human herpesvirus 6 and 7. Antiviral Chem Chemother 1997; 8:24–31
    [Google Scholar]
16. Andrei G., Snoeck R., Vandeputte M., De Clercq E. Activities of various compounds against murine and primate polyoma-viruses. Antimicrob Agents Chemother 1997; 41:587–593
    [Google Scholar]
17. De Oliveira C. B. R., Stevenson D., LaBree L., McDonnell P. J., Trousdale M. D. Evaluation of cidofovir (HPMPC, GS-504) against adenovirus type 5 infection in vitro and in a New Zealand rabbit ocular model. Antiviral Res 1996; 31:165–172
    [Google Scholar]
18. Tsai C. C., Follis K. E., Sabo A. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science 1995; 270:1197–1199
    [Google Scholar]
19. Van Rompay K. K. A., Cherrington J. M., Marthas M. L. 9-[2-(phosphonomethoxy)propyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques. Antimicrob Agents Chemother 1996; 40:2586–2591
    [Google Scholar]
20. Tsai C. C., Follis K. E., Beck T. W., Sabo A., Bischofberger N., Dailey P. J. Effects of (R)-9-(2-phosphonylmethoxypropyl)ade-nine monotherapy on chronic SIV infection in macaques. AIDS Res Hum Retroviruses 1997; 13:707–712
    [Google Scholar]
21. Lalezari J. P., Stagg R. J., Kuppermann B. D. Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. Ann Intern Med 1997; 126:257–263
    [Google Scholar]
22. Studies of Ocular Complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS: the HPMPC peripheral cytomegalovirus retinitis trial. Ann Intern Med 1997; 126:264–274
    [Google Scholar]
23. Van Cutsem E., Snoeck R., Van Ranst M. Successful treatment of a squamous papilloma of the hypopharynx-esophagus by local injections of (S)-l-(3-hydroxy-2-phos-phonylmethoxypropyl)cytosine. J Med Virol 1995; 45:230–235
    [Google Scholar]
24. De Clercq E. Development of resistance of human immunodeficiency virus (HIV) to anti-HIV agents: how to prevent the problem?. Int J Antimicrob Agents 1997; 9:21–36
    [Google Scholar]
25. Cherrington J. M., Mulato A. S., Fuller M. D., Chen M. S. Novel mutation (K70E) in human immunodeficiency virus type 1 reverse transcriptase confers decreased susceptibility to 9-[2-(phosphonomethoxy)ethyl]adenine in vitro. Antimicrob Agents Chemother 1996; 40:2212–2216
    [Google Scholar]
26. Cherrington J. M. Human cytomegalovirus: resistance profile of cidofovir. Int Antiviral News 1997; 5:91–92
    [Google Scholar]